Using protein biomarkers to improve lung cancer screening decisions
Official title: The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening
Funded at International Agency for Res on Cancer · NIH-10909840 · Data updated 2026-11-12
The LEAP project is looking to improve lung cancer screening by testing a new set of protein markers in blood samples to see if checking these markers multiple times can help doctors make better decisions about when to start screening and when to take a closer look at lung nodules, ultimately aiming to create more tailored and effective screening for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project start | September 8, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $452,301 |
| NIH project number | 5R01CA262164-03 |
| Project ID | NIH-10909840 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include current and former smokers who are at risk for lung cancer.
✕Less likely to help
Patients who do not smoke or have never smoked may not benefit from this research.
What this research studies
The Lung EArly Proteins (LEAP) project aims to enhance lung cancer screening by utilizing a novel panel of protein biomarkers. This research focuses on optimizing the decision-making process for initiating screening and determining when to biopsy lung nodules. By analyzing blood samples from lung cancer patients and controls, the project seeks to establish whether repeated measurements of these biomarkers can provide better predictive accuracy for lung cancer development compared to a single measurement. The findings could lead to more personalized and effective screening strategies for at-risk individuals.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely lung cancer screenings, potentially saving lives through earlier detection.
How similar studies have gone: Previous research has shown promise in using biomarkers for cancer detection, suggesting that this approach could be effective.
Where this research is happening
-
International Agency for Res on Cancer
Lyon, France Active
Researchers
- Principal investigator: Robbins, Hilary a. — International Agency for Res on Cancer
- Study coordinator: Robbins, Hilary a.
Related research
Other NIH-funded projects on the same topics.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Integrated approach to lung screening and quitting for African Americans
A multi-level program aims to boost LDCT lung cancer screening uptake and help African American smokers quit, with support from a comprehensive community-focused plan.
-
Population health approach to boost lung cancer screening at community clinics
A large Utah project aims to help community clinics reach more eligible adults to get low-dose CT lung cancer screening.
-
Group-based tobacco treatment for older adults after lung cancer screening
A study tests a group-based tobacco cessation program for older adults who are getting lung cancer screening to help them quit smoking.
-
Personalized Lung Cancer Screening for Veterans
Aimed at improving who gets screened and how lung cancer is diagnosed among Veterans using personalized tools.
-
Proteogenomic framework to improve lung cancer screening with biomarkers
A biomarker-based approach aims to refine LDCT lung cancer screening so more cancers are caught early while reducing unnecessary procedures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.